Antisense Therapeutics Limited  

(Public, ASX:ANP)   Watch this stock  
Find more results for ANP
+0.015 (10.34%)
Apr 16 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.15 - 0.16
52 week 0.09 - 0.23
Open 0.15
Vol / Avg. 95,026.00/821,127.00
Mkt cap 23.06M
P/E     -
Div/yield     -
EPS -0.02
Shares 144.10M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -274.48% -189.54%
Operating margin -279.20% -190.44%
EBITD margin - -189.82%
Return on average assets -60.22% -45.08%
Return on average equity -68.93% -49.53%
Employees 5 -
CDP Score - -


6 Wallace Avenue, Toorak
+61-3-98278999 (Phone)
+61-3-98271166 (Fax)

Website links


Antisense Therapeutics Limited is an Australia-based company engaged in the research and development of novel antisense pharmaceuticals. The Company operates in two segments: Multiple Sclerosis and Growth and Sight Disorders. The Company's product development product pipeline includes ATL1101 for prostate cancer, ATL1102 for asthma, ATL1102 for multiple sclerosis and ATL1103 for growth and sight disorders. ATL1103 product's patents have been granted in the United States, Australia, Japan and New Zealand. ATL1102 product's patents have been granted in the United States, Australia, Japan, Denmark, Finland and France. ATL1101 product's patents have been granted in Australia, Canada, Japan and New Zealand.

Officers and directors

Phillip Hains Chief Financial Officer, Company Secretary
Mark Diamond Managing Director, Executive Director
George Tachas Ph.D. Director - Drug Discovery & Patents
Robert W. Moses Independent Non-Executive Chairman of the Board
Christopher Belyea Independent Non-Executive Director
Graham F. Mitchell Independent Non-Executive Director